DDX39B

Summary

DDX39B (DExD-box helicase 39B, HGNC:13917) is a protein-coding gene on chromosome 6p21.33, encoding Spliceosome RNA helicase DDX39B (Q13838). Involved in nuclear export of spliced and unspliced mRNA. It is a selective cancer dependency (DepMap: 63.2% of cell lines).

This gene encodes a member of the DEAD box family of RNA-dependent ATPases that mediate ATP hydrolysis during pre-mRNA splicing. The encoded protein is an essential splicing factor required for association of U2 small nuclear ribonucleoprotein with pre-mRNA, and it also plays an important role in mRNA export from the nucleus to the cytoplasm. This gene belongs to a cluster of genes localized in the vicinity of the genes encoding tumor necrosis factor alpha and tumor necrosis factor beta. These genes are all within the human major histocompatibility complex class III region. Mutations in this gene may be associated with rheumatoid arthritis. Alternative splicing results in multiple transcript variants. Related pseudogenes have been identified on both chromosomes 6 and 11. Read-through transcription also occurs between this gene and the upstream ATP6V1G2 (ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2) gene.

Source: NCBI Gene 7919 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 32
• Clinical variants (ClinVar): 3 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 63.2% of screened cell lines
• MANE Select transcript: NM_004640

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13917
Approved symbol	DDX39B
Name	DExD-box helicase 39B
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	D6S81E, Uap56
Ensembl gene	ENSG00000198563
Ensembl biotype	protein_coding
OMIM	142560
Entrez	7919

Gene structure

Transcript identifiers

Ensembl transcripts: 68 — 61 protein_coding, 5 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000376177, ENST00000396172, ENST00000417023, ENST00000418897, ENST00000419020, ENST00000419338, ENST00000427214, ENST00000428098, ENST00000428450, ENST00000431908, ENST00000449757, ENST00000456662, ENST00000456976, ENST00000458640, ENST00000462256, ENST00000462421, ENST00000474961, ENST00000478365, ENST00000481456, ENST00000482195, ENST00000484566, ENST00000866323, ENST00000866324, ENST00000866325, ENST00000866326, ENST00000866327, ENST00000866328, ENST00000866329, ENST00000866330, ENST00000866331, ENST00000866332, ENST00000866333, ENST00000866334, ENST00000866335, ENST00000866336, ENST00000866337, ENST00000866338, ENST00000866339, ENST00000923348, ENST00000923349, ENST00000923350, ENST00000923351, ENST00000923352, ENST00000923353, ENST00000923354, ENST00000923355, ENST00000923356, ENST00000923357, ENST00000923358, ENST00000923359, ENST00000923360, ENST00000923361, ENST00000923362, ENST00000923363, ENST00000923364, ENST00000923365, ENST00000963245, ENST00000963246, ENST00000963247, ENST00000963248, ENST00000963249, ENST00000963250, ENST00000963251, ENST00000963252, ENST00000963253, ENST00000963254, ENST00000963255, ENST00000963256

RefSeq mRNA: 2 — MANE Select: NM_004640 NM_004640, NM_080598

CCDS: CCDS4697

Canonical transcript exons

ENST00000396172 — 11 exons

Exon	Start	End
ENSE00001763907	31541950	31542003
ENSE00003467329	31539147	31539274
ENSE00003520497	31538763	31538855
ENSE00003532613	31540322	31540664
ENSE00003625497	31531053	31531197
ENSE00003637164	31535367	31535485
ENSE00003638363	31536500	31536683
ENSE00003664572	31531296	31531405
ENSE00003785849	31530779	31530926
ENSE00003791442	31532780	31532911
ENSE00003850394	31530226	31530450

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 99.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 248.3796 / max 2478.9709, expressed in 1827 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72690	244.1381	1827
72689	1.5638	1063
72687	0.7386	289
72691	0.4571	174
203943	0.4458	200
72686	0.4131	192
72684	0.2876	125
72692	0.1814	71
72683	0.1542	63

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.55	gold quality
adenohypophysis	UBERON:0002196	99.48	gold quality
ventricular zone	UBERON:0003053	99.48	gold quality
ganglionic eminence	UBERON:0004023	99.48	gold quality
right uterine tube	UBERON:0001302	99.47	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.42	gold quality
right lobe of thyroid gland	UBERON:0001119	99.41	gold quality
left lobe of thyroid gland	UBERON:0001120	99.41	gold quality
left ovary	UBERON:0002119	99.38	gold quality
cerebellar hemisphere	UBERON:0002245	99.38	gold quality
body of uterus	UBERON:0009853	99.38	gold quality
right ovary	UBERON:0002118	99.37	gold quality
endocervix	UBERON:0000458	99.36	gold quality
mucosa of stomach	UBERON:0001199	99.35	gold quality
cortical plate	UBERON:0005343	99.34	gold quality
cerebellar cortex	UBERON:0002129	99.32	gold quality
left uterine tube	UBERON:0001303	99.31	gold quality
metanephros cortex	UBERON:0010533	99.31	gold quality
muscle layer of sigmoid colon	UBERON:0035805	99.28	gold quality
small intestine Peyer’s patch	UBERON:0003454	99.27	gold quality
lower esophagus mucosa	UBERON:0035834	99.26	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.26	gold quality
tibial nerve	UBERON:0001323	99.25	gold quality
skin of abdomen	UBERON:0001416	99.25	gold quality
upper lobe of left lung	UBERON:0008952	99.24	gold quality
lower esophagus	UBERON:0013473	99.24	gold quality
lower esophagus muscularis layer	UBERON:0035833	99.24	gold quality
ectocervix	UBERON:0012249	99.23	gold quality
skin of leg	UBERON:0001511	99.20	gold quality
body of pancreas	UBERON:0001150	99.19	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	83.10
E-ANND-3	yes	6.47
E-GEOD-93593	no	6.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting DDX39B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-642A-3P	99.23	67.67	1258
HSA-MIR-642B-3P	99.23	67.67	1258
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-876-3P	98.76	68.23	945
HSA-MIR-323A-5P	98.59	65.13	651
HSA-MIR-6852-3P	98.54	67.60	1468
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-3909	97.55	66.78	887
HSA-MIR-6835-5P	95.81	64.27	500

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 63.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• BAT1 transcription on the 7.1 AH (diabetes-resistant ancestral haplotype)is modified by interactions involving DNA flanking positions -22 and -348 in the promotor (PMID:15028669)
• The structures of UAP56/Sub2(BAT1) reveal a unique spatial arrangement of the two conserved helicase domains, and ADP-binding induces significant conformational changes of key residues in the ATP-binding pocket (PMID:15585580)
• recruitment of the human TREX complex to spliced mRNA is not directly coupled to transcription, but is instead coupled to transcription indirectly through splicing (PMID:15998806)
• UAP56 provides a herpesviral regulatory protein with access to a conserved cellular transport system in order to promote nuclear export of unspliced RNA. (PMID:16478985)
• Reducing the expression of UAP56 and URH49 resulted in a reduction in reporter gene expression as well as cell death within 72 h suggest that both helicases have essential but largely overlapping functions in the processing and export of mammalian mRNAs. (PMID:16949217)
• Minor homozygous genotypes of polymorphisms in BAT1 were associated with moderately protective effects against myocardial infarction. (PMID:17517687)
• UAP56 has ATPase and helicase activity and roles in spliceosome assembly and mRNA export (PMID:17562711)
• The role of BAT1 in the regulation of tumor necrosis factor-a suggests that BAT1 may regulate the inflammatory response observed in patients with rheumatoid arthritis. (PMID:18381799)
• The equilibrium binding of UAP56 in complexes at speckled domains was directly regulated by ATP binding. (PMID:18411249)
• hUAP56 first interacts with U2AF(65) in an ATP-dependent manner, and subsequently with U4/U6 snRNAs to facilitate stepwise assembly of the spliceosome. (PMID:18593880)
• APOE epsilon4 was associated with an independent increase in risk for Alzheimer’s disease (AD) in individuals with TNFA -850*2, while carriage of BAT1 -22*2 reduced the risk for AD, independent of APOE epsilon4 genotype (PMID:18715507)
• The authors demonstrate that ORF57 recruits several members of hTREX, namely Aly, UAP56 and hTHO-complex proteins, onto the viral mRNAs to assemble an export-competent ribonucleoprotein particle. (PMID:19264631)
• This report summarizes recent evidence for the role of UAP56 in pre-mRNA splicing and nuclear export. (PMID:19403039)
• UAP56 is an important regulator of protein synthesis and plays an important role in the regulation of cardiomyocyte growth. (PMID:20116367)
• Data show that the two closely related RNA helicases UAP56 and URH49 have evolved to form distinct mRNA export machineries, which regulate mitosis at different steps. (PMID:20573985)
• Using a UL69 viral mutant that is unable to bind UAP56 and URH49, the authors demonstrated that UL69’s interaction with UAP56 or URH49 does not contribute to the growth phenotype associated with the UL69 deletion mutant. (PMID:20610707)
• UAP56 binding was shown to represent a unique characteristic of members of the genus Cytomegalovirus that is required for efficient replication of HCMV and required for nuclear mRNA export. (PMID:21147923)
• These findings demonstrate that replication of the inlfuenza virus genome is followed by its encapsidation by NP in collaboration with its chaperone UAP56. (PMID:21507964)
• In summary, these data demonstrate that UAP56 is utilized by influenza A viruses to prevent the formation of dsRNA and, hence, the activation of the innate immune response. (PMID:21680511)
• UAP56 and URH49 exhibit an intrinsic CRM1-independent nucleocytoplasmic shuttling (PMID:21799930)
• Mx proteins exert their antiviral activity against IAV by interfering with the function of the RNA helicases UAP56 and URH49 (PMID:21859714)
• We unravel the role of unexplored immunologically important genes, BAT1 and BTNL2, and the haplotypes of the significantly associated SNPs therein, to understand susceptibility to the disease, leprosy and its differential severity. (PMID:22071774)
• these data identify UAP56 as an important binding partner of Bcr and a novel target for inhibiting vascular smooth muscle cell proliferation. (PMID:22446327)
• The G allele of DDX39B-22C > G was associated with absent or decreased manifestations of vivax malaria and the C allele was a risk factor for disease complications. (PMID:25038626)
• However, no significant association was observed between the DDX39B -22 G/C polymorphism in the cases and controls. Furthermore, it is clarified that the protective effect of IL-4 -590 is independent from APOE protective genotypes (PMID:26265379)
• DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation (PMID:28025139)
• Distinct features of RNA influence and ATPase efficiency between UAP56 and TcSub2 may reflect distinct structures for functional sites of TcSub2. For this reason, ligand-based or structure-based methodologies can be applied to investigate the potential of TcSub2 as a target for new drugs. (PMID:28212935)
• Study showed that a genetic variant in the 5’ UTR of DDX39B reduces translation of DDX39B mRNAs and increases multiple sclerosis (MS) risk. Importantly, this DDX39B variant showed strong genetic & functional epistasis with allelic variants in IL7R exon 6; study establishes the occurrence of biological epistasis in humans & provides mechanistic insight into the regulation of IL7R exon 6 splicing & its impact on MS risk. (PMID:28340352)
• DDX39B promotes proliferation and colony forming potential of cells and its levels are significantly elevated in diverse cancer types.DDX39B regulates the pre-ribosomal RNA levels. (PMID:30176153)
• Cellular mRNA export factor UAP56 recognizes nucleic acid binding site of influenza virus NP protein. (PMID:32085897)
• THE BRANCHED-CHAIN AMINO ACID TRANSAMINASE 1 -23C/G POLYMORPHISM CONFERS PROTECTION AGAINST ACUTE CORONARY SYNDROME. (PMID:32132739)
• Cellular UAP56 interacts with the HBx protein of the hepatitis B virus and is involved in viral RNA nuclear export in hepatocytes. (PMID:32169426)
• DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-kappaB and sensitize to alkylating chemotherapy. (PMID:32209106)
• UAP56/DDX39B is a major cotranscriptional RNA-DNA helicase that unwinds harmful R loops genome-wide. (PMID:32439635)
• Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. (PMID:32989256)
• The DDX39B/FUT3/TGFbetaR-I axis promotes tumor metastasis and EMT in colorectal cancer. (PMID:33436563)
• DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC. (PMID:34382524)
• DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. (PMID:35973989)
• RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma. (PMID:36109793)
• DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. (PMID:37052853)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ddx39b	ENSDARG00000036069
mus_musculus	Ddx39b	ENSMUSG00000019432
rattus_norvegicus	Ddx39b	ENSRNOG00000000841

Paralogs (38): DDX20 (ENSG00000064703), DDX3Y (ENSG00000067048), DDX1 (ENSG00000079785), DDX43 (ENSG00000080007), DDX18 (ENSG00000088205), DDX24 (ENSG00000089737), DDX17 (ENSG00000100201), DDX49 (ENSG00000105671), DDX50 (ENSG00000107625), DDX5 (ENSG00000108654), DDX25 (ENSG00000109832), DDX6 (ENSG00000110367), DDX55 (ENSG00000111364), DDX59 (ENSG00000118197), DDX54 (ENSG00000123064), DDX39A (ENSG00000123136), DDX27 (ENSG00000124228), DDX31 (ENSG00000125485), DDX56 (ENSG00000136271), EIF4A3 (ENSG00000141543), DDX46 (ENSG00000145833), DDX4 (ENSG00000152670), EIF4A2 (ENSG00000156976), DDX19B (ENSG00000157349), EIF4A1 (ENSG00000161960), DDX21 (ENSG00000165732), DDX19A (ENSG00000168872), TDRD12 (ENSG00000173809), DDX23 (ENSG00000174243), DDX10 (ENSG00000178105), DDX28 (ENSG00000182810), DDX41 (ENSG00000183258), DDX53 (ENSG00000184735), DDX51 (ENSG00000185163), DDX42 (ENSG00000198231), DDX47 (ENSG00000213782), DDX3X (ENSG00000215301), DDX52 (ENSG00000278053)

Protein

Protein identifiers

Spliceosome RNA helicase DDX39B — Q13838 (reviewed: Q13838)

Alternative names: 56 kDa U2AF65-associated protein, ATP-dependent RNA helicase p47, DEAD box protein UAP56, HLA-B-associated transcript 1 protein

All UniProt accessions (15): A0A024RCM3, A0A0A0MT12, Q13838, F6QYI9, F6R6M7, F6S2B7, F6S4E6, F6SXL5, F6TRA5, F6U6E2, F6UJC5, F6WLT2, H0Y400, H0YCC6, Q5STU3

UniProt curated annotations — full annotation on UniProt →

Function. Involved in nuclear export of spliced and unspliced mRNA. Component of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and specifically associates with spliced mRNA and not with unspliced pre-mRNA. The TREX complex is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5’ end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NXF1 pathway. The THOC1-THOC2-THOC3 core complex alone is sufficient to promote ATPase activity of DDX39B; in the complex THOC2 is the only component that directly interacts with DDX39B. Associates with SARNP/CIP29, which facilitates RNA binding of DDX39B and likely plays a role in mRNA export. May undergo several rounds of ATP hydrolysis during assembly of TREX to drive subsequent loading of components such as ALYREF/THOC4 and CHTOP onto mRNA. Also associates with pre-mRNA independent of ALYREF/THOC4. Involved in the nuclear export of intronless mRNA; the ATP-bound form is proposed to recruit export adapter ALYREF/THOC4 to intronless mRNA; its ATPase activity is cooperatively stimulated by RNA and ALYREF/THOC4 and ATP hydrolysis is thought to trigger the dissociation from RNA to allow the association of ALYREF/THOC4 and the NXF1-NXT1 heterodimer. Involved in transcription elongation and genome stability. Splice factor that is required for the first ATP-dependent step in spliceosome assembly and for the interaction of U2 snRNP with the branchpoint. Has both RNA-stimulated ATP binding/hydrolysis activity and ATP-dependent RNA unwinding activity. Even with the stimulation of RNA, the ATPase activity is weak. Can only hydrolyze ATP but not other NTPs. The RNA stimulation of ATPase activity does not have a strong preference for the sequence and length of the RNA. However, ssRNA stimulates the ATPase activity much more strongly than dsRNA. Can unwind 5’ or 3’ overhangs or blunt end RNA duplexes in vitro. The ATPase and helicase activities are not influenced by U2AF2; the effect of ALYREF/THOC4 is reported conflictingly with [PubMed:23299939] reporting a stimulatory effect. (Microbial infection) The TREX complex is essential for the export of Kaposi’s sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production.

Subunit / interactions. Homodimer, and heterodimer with DDX39A. DDX39B interacts with the THO subcomplex to form the THO-DDX39B complex which multimerizes into a 28-subunit tetrameric assembly. Component of the transcription/export (TREX) complex at least composed of ALYREF/THOC4, DDX39B, SARNP/CIP29, CHTOP and the THO subcomplex; in the complex interacts with THOC2. THOC1-THOC2-THOC3-DDX39B subcomplex is sufficient for the interaction with export factor NXF1-NXT1. TREX seems to have a dynamic structure involving ATP-dependent remodeling. Within the TREX complex bridges ALYREF/THOC4 and the THO subcomplex, and, in a ATP-dependent manner, ALYREF/THOC4 and SARNP/CIP29. Component of the spliceosome. Interacts directly with U2AF2. Interacts with RBM8A, RNPS1 and SRRM1, FYTTD1/UIF, THOC1, MX1 and POLDIP3. Interacts with LUZP4. Interacts with SARNP/CIP29 (via the C-terminal domain); the interaction is direct and facilitates RNA binding of DDX39B. (Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL69.

Subcellular location. Nucleus. Nucleus speckle. Cytoplasm.

Domain organisation. The helicase C-terminal domain mediates interaction with ALYREF/THOC4.

Similarity. Belongs to the DEAD box helicase family. DECD subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q13838-1	1	yes
Q13838-2	2

RefSeq proteins (2): NP_004631, NP_542165 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001650	Helicase_C-like	Domain
IPR011545	DEAD/DEAH_box_helicase_dom	Domain
IPR014001	Helicase_ATP-bd	Domain
IPR014014	RNA_helicase_DEAD_Q_motif	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00270, PF00271

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (65 total): helix 20, strand 19, mutagenesis site 7, modified residue 5, domain 2, turn 2, short sequence motif 2, initiator methionine 1, chain 1, cross-link 1, splice variant 1, sequence conflict 1, region of interest 1, compositionally biased region 1, binding site 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
1T5I	X-RAY DIFFRACTION	1.9
1T6N	X-RAY DIFFRACTION	1.94
1XTI	X-RAY DIFFRACTION	1.95
1XTK	X-RAY DIFFRACTION	2.4
8ENK	X-RAY DIFFRACTION	2.5
1XTJ	X-RAY DIFFRACTION	2.7
9DLP	ELECTRON MICROSCOPY	2.79
9T6L	ELECTRON MICROSCOPY	2.9
9DLV	ELECTRON MICROSCOPY	2.97
9T6N	ELECTRON MICROSCOPY	3
9DLR	ELECTRON MICROSCOPY	3.08
7APK	ELECTRON MICROSCOPY	3.3
9UPB	ELECTRON MICROSCOPY	3.41
7ZNL	ELECTRON MICROSCOPY	3.45
8R7K	ELECTRON MICROSCOPY	3.5
7ZNK	ELECTRON MICROSCOPY	3.9
8R7L	ELECTRON MICROSCOPY	4.12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13838-F1	85.34	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 89–96

Post-translational modifications (6): 36, 38, 41, 172, 36, 2

Mutagenesis-validated functional residues (7):

Position	Phenotype
94–96	loss of atpase and helicase activity.
95	loss of atpase and helicase activity.
197	loss of atpase and helicase activity.
198	no effect on atpase activity.
199	increased atpase activity and loss of helicase activity.
228–230	decreased atpase activity and loss of helicase activity.
283	abolishes interaction with sarnp; when associated with 2-a–t-258 del.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-159236	Transport of Mature mRNA derived from an Intron-Containing Transcript
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-72187	mRNA 3’-end processing
R-HSA-9013418	RHOBTB2 GTPase cycle
R-HSA-73856	RNA Polymerase II Transcription Termination

MSigDB gene sets: 252 (showing top): HORIUCHI_WTAP_TARGETS_DN, MORF_SMC1L1, MORF_SNRP70, MORF_UBE2I, MATTIOLI_MGUS_VS_PCL, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_HDAC1, MORF_UBE2N, HSIAO_HOUSEKEEPING_GENES, MORF_HDAC2, PUJANA_CHEK2_PCC_NETWORK, GOBP_NUCLEAR_TRANSPORT, MORF_TERF1, RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP, MORF_CTBP1

GO Biological Process (7): spliceosomal complex assembly (GO:0000245), mRNA splicing, via spliceosome (GO:0000398), RNA export from nucleus (GO:0006405), mRNA export from nucleus (GO:0006406), RNA splicing (GO:0008380), mRNA processing (GO:0006397), mRNA transport (GO:0051028)

GO Molecular Function (15): RNA binding (GO:0003723), RNA helicase activity (GO:0003724), mRNA binding (GO:0003729), ATP binding (GO:0005524), ATP-dependent activity, acting on RNA (GO:0008186), ATP hydrolysis activity (GO:0016887), U6 snRNA binding (GO:0017070), U4 snRNA binding (GO:0030621), identical protein binding (GO:0042802), ATP-dependent protein binding (GO:0043008), nucleotide binding (GO:0000166), nucleic acid binding (GO:0003676), helicase activity (GO:0004386), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (8): transcription export complex (GO:0000346), nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), U4 snRNP (GO:0005687), U6 snRNP (GO:0005688), cytoplasm (GO:0005737), nuclear speck (GO:0016607)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Transport of Mature Transcript to Cytoplasm	1
mRNA Splicing	1
Processing of Capped Intron-Containing Pre-mRNA	1
RHOBTB GTPase Cycle	1
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	3
RNA transport	2
RNA processing	2
snRNA binding	2
protein binding	2
binding	2
nuclear protein-containing complex	2
cellular anatomical structure	2
spliceosomal snRNP complex	2
mRNA splicing, via spliceosome	1
protein-RNA complex assembly	1
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
nuclear export	1
RNA export from nucleus	1
gene expression	1
mRNA transport	1
mRNA metabolic process	1
nucleic acid binding	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
RNA binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
catalytic activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
ribonucleoprotein complex	1
Lsm2-8 complex	1
intracellular anatomical structure	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

4353 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DDX39B	ALYREF	Q86V81	999
DDX39B	THOC2	Q8NI27	998
DDX39B	THOC3	Q96J01	998
DDX39B	THOC1	Q96FV9	995
DDX39B	SARNP	P82979	995
DDX39B	CHTOP	Q9Y3Y2	982
DDX39B	U2AF2	P26368	974
DDX39B	FYTTD1	Q96QD9	972
DDX39B	POLDIP3	Q9BY77	964
DDX39B	THOC5	Q13769	927
DDX39B	RAE1	P78406	914
DDX39B	NXF1	Q9UBU9	881
DDX39B	THOC7	Q6I9Y2	876
DDX39B	THOC6	Q86W42	873
DDX39B	HNRNPA1	P09651	842

IntAct

227 interactions, top by confidence:

A	B	Type	Score
THOC1	THOC5	psi-mi:“MI:0914”(association)	0.930
DDX39B	CHTOP	psi-mi:“MI:0915”(physical association)	0.870
SARNP	DDX39B	psi-mi:“MI:0915”(physical association)	0.800
DDX39B	THOC5	psi-mi:“MI:0915”(physical association)	0.800
DDX39A	DDX39B	psi-mi:“MI:0915”(physical association)	0.770
DDX39B	ALYREF	psi-mi:“MI:0914”(association)	0.770
DDX39A	DDX39B	psi-mi:“MI:0914”(association)	0.770
SARNP	DDX39A	psi-mi:“MI:0914”(association)	0.740
MED19	MED19	psi-mi:“MI:0914”(association)	0.730
DDX39B	FYTTD1	psi-mi:“MI:0915”(physical association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
DDX39B	DDX39B	psi-mi:“MI:0915”(physical association)	0.670
SNRPA	DDX39B	psi-mi:“MI:0915”(physical association)	0.670
THOC1	EIF4A3	psi-mi:“MI:0914”(association)	0.660
NCBP1	KPNA3	psi-mi:“MI:0914”(association)	0.640
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
SF3B1	SAP18	psi-mi:“MI:0914”(association)	0.640
THOC1	DDX39A	psi-mi:“MI:0914”(association)	0.640
	DDX39B	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (1020): DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-MS), DDX39B (Affinity Capture-Western), LUZP4 (Reconstituted Complex), DDOST (Co-fractionation), DDX39B (Co-fractionation), DDX39B (Co-fractionation), DDX39B (Co-fractionation), DDX39B (Co-fractionation), DDX39B (Co-fractionation)

ESM2 similar proteins: A1CMQ7, A1DL85, A2R0B5, A3LST5, A4RBS3, A5DDN0, A5E3W5, A6R603, A6ZXP4, A7EIX7, A7TJT7, A7TLA0, O00148, O13792, P0CQ96, P0CQ97, P54823, P60024, Q07478, Q0CGJ9, Q0JM17, Q0TXZ2, Q13838, Q18212, Q1DI07, Q27268, Q29024, Q29S22, Q2H4D0, Q2U6P7, Q3T147, Q4WCW2, Q56XG6, Q5ASK8, Q5JK84, Q5RE47, Q5TM17, Q5U216, Q5WR10, Q5ZHZ0

Diamond homologs: A1C595, A1CJT5, A1CMQ7, A1D071, A1D7N3, A1DL85, A2QEN5, A2R0B5, A3GFI4, A3GFV3, A3LST5, A4QU31, A4QVP2, A4RBS3, A5AAE5, A5DB98, A5DDN0, A5DE68, A5DVM3, A5E3W5, A6QSQ0, A6R603, A6RJ45, A6ZQJ1, A6ZXP4, A7EGL7, A7EIX7, A7EM88, A7TJT7, A7TK55, A7TLA0, O00148, O02494, O13792, P0CQ70, P0CQ71, P0CQ96, P0CQ97, P10081, P10630

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DDX39B	“form complex”	“TREX complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 167 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	10	32.0×	3e-11
mRNA 3’-end processing	19	31.4×	3e-21
Metabolism of non-coding RNA	5	26.7×	6e-05
RNA Polymerase II Transcription Termination	14	25.8×	2e-14
Transport of Mature mRNA derived from an Intron-Containing Transcript	17	21.8×	3e-16
Processing of Capped Intron-Containing Pre-mRNA	21	14.5×	2e-16
HIV Transcription Elongation	5	14.1×	1e-03
Nuclear RNA decay	5	13.0×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
mRNA export from nucleus	16	32.2×	3e-17
U2-type prespliceosome assembly	5	21.2×	7e-04
spliceosomal snRNP assembly	5	19.8×	8e-04
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay	5	15.9×	2e-03
mRNA splicing, via spliceosome	20	12.5×	9e-14
RNA splicing	17	10.2×	4e-10
mRNA processing	14	7.5×	2e-06
response to ethanol	7	7.0×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

3 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2519 predictions. Top by Δscore:

Variant	Effect	Δscore
6:31530773:A:AC	donor_gain	1.0000
6:31530774:C:CC	donor_gain	1.0000
6:31530774:CTCA:C	donor_gain	1.0000
6:31530775:TCA:T	donor_loss	1.0000
6:31530776:CA:C	donor_loss	1.0000
6:31530777:A:AC	donor_gain	1.0000
6:31530777:AC:A	donor_loss	1.0000
6:31530778:C:CA	donor_gain	1.0000
6:31530778:C:CT	donor_gain	1.0000
6:31530778:CT:C	donor_gain	1.0000
6:31530778:CTG:C	donor_gain	1.0000
6:31530778:CTGT:C	donor_gain	1.0000
6:31530778:CTGTA:C	donor_gain	1.0000
6:31530926:CCT:C	acceptor_loss	1.0000
6:31530927:C:CG	acceptor_loss	1.0000
6:31530927:CT:C	acceptor_loss	1.0000
6:31531047:GTTTA:G	donor_loss	1.0000
6:31531048:TTTA:T	donor_loss	1.0000
6:31531048:TTTAC:T	donor_loss	1.0000
6:31531049:TTA:T	donor_loss	1.0000
6:31531049:TTAC:T	donor_loss	1.0000
6:31531050:TACC:T	donor_loss	1.0000
6:31531050:TACCC:T	donor_loss	1.0000
6:31531051:A:AC	donor_gain	1.0000
6:31531051:A:AG	donor_loss	1.0000
6:31531051:A:AT	donor_loss	1.0000
6:31531051:AC:A	donor_gain	1.0000
6:31531052:C:CC	donor_gain	1.0000
6:31531052:CC:C	donor_gain	1.0000
6:31531197:CC:C	acceptor_loss	1.0000

AlphaMissense

2862 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:31530828:A:C	F407L	1.000
6:31530828:A:T	F407L	1.000
6:31530830:A:G	F407L	1.000
6:31530906:A:C	F381L	1.000
6:31530906:A:T	F381L	1.000
6:31530908:A:G	F381L	1.000
6:31531373:G:C	C300W	1.000
6:31538835:A:C	C120W	1.000
6:31539206:C:G	G94R	1.000
6:31539206:C:T	G94R	1.000
6:31540338:A:C	F65L	1.000
6:31540338:A:T	F65L	1.000
6:31540340:A:G	F65L	1.000
6:31530832:C:G	R406P	0.999
6:31530850:A:G	L400P	0.999
6:31530883:G:T	T389K	0.999
6:31530889:G:T	A387D	0.999
6:31530895:C:T	G385D	0.999
6:31530896:C:G	G385R	0.999
6:31530913:C:T	G379D	0.999
6:31531054:C:G	R374P	0.999
6:31531058:G:C	H373D	0.999
6:31531092:A:C	N361K	0.999
6:31531092:A:T	N361K	0.999
6:31531127:C:G	G350R	0.999
6:31531150:A:T	V342E	0.999
6:31531153:A:G	L341P	0.999
6:31531374:C:T	C300Y	0.999
6:31531394:A:C	F293L	0.999
6:31531394:A:T	F293L	0.999

dbSNP variants (sampled 300 via entrez): RS1000206682 (6:31543039 C>G,T), RS1000501115 (6:31537902 A>G), RS1000639768 (6:31530616 T>A), RS1000684336 (6:31530463 C>T), RS1000783743 (6:31537688 A>G), RS1001010377 (6:31531062 G>A), RS1001076799 (6:31543436 C>G,T), RS1001148780 (6:31537720 G>A,C), RS1001362107 (6:31533826 C>A), RS1001426600 (6:31531965 A>G), RS1001624394 (6:31538593 G>A,C), RS1002055197 (6:31538266 C>G), RS1002358117 (6:31537280 A>G,T), RS1002767048 (6:31532316 G>A), RS1003081366 (6:31535838 T>C)

Disease associations

OMIM: gene MIM:142560 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

32 associations (top):

Study	Trait	p-value
GCST000308_1	AIDS progression	3.000000e-19
GCST001239_1	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	2.000000e-08
GCST001363_6	Atopic dermatitis	2.000000e-06
GCST003092_22	Myositis	3.000000e-49
GCST003092_23	Myositis	6.000000e-49
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_265	Autism spectrum disorder or schizophrenia	7.000000e-14
GCST004521_27	Autism spectrum disorder or schizophrenia	1.000000e-09
GCST004521_3	Autism spectrum disorder or schizophrenia	2.000000e-15
GCST004521_70	Autism spectrum disorder or schizophrenia	8.000000e-20
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST004599_42	Mean platelet volume	2.000000e-24
GCST004609_64	Monocyte percentage of white cells	4.000000e-13
GCST004863_114	Mosquito bite size	2.000000e-17
GCST008916_111	Asthma	2.000000e-14
GCST008916_114	Asthma	1.000000e-09
GCST008916_30	Asthma	1.000000e-09
GCST008917_2	Asthma (childhood onset)	4.000000e-07
GCST008921_1	Asthma and major depressive disorder	2.000000e-16
GCST010725_43	Malaria	5.000000e-07
GCST010725_62	Malaria	3.000000e-06
GCST90002385_552	High light scatter reticulocyte count	5.000000e-24
GCST90002397_119	Mean spheric corpuscular volume	2.000000e-27

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes
EFO:0008378	mosquito bite reaction size measurement
EFO:0007986	reticulocyte count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066325 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2734583	DDX39B, SNORD117	3	3.75	1	allopurinol

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.02	Kd	956.8	nM	CHEMBL5653589
6.02	ED50	956.8	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148222: Binding affinity to human DDX39B incubated for 45 mins by Kinobead based pull down assay	kd	0.9568	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	2
Valproic Acid	decreases expression, affects expression	2
bisphenol F	increases expression	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
trichostatin A	affects cotreatment, decreases expression	1
beta-lapachone	decreases expression, increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
vanadyl sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	decreases expression	1
2-amino-14,16-dimethyloctadecan-3-ol	decreases expression	1
bromovanin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Vehicle Emissions	increases expression	1
Caffeine	decreases phosphorylation	1
Calcium Chloride	increases expression	1
Carcinogens	decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Doxorubicin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651264	Binding	Binding affinity to human DDX39B incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

475 cell lines: 475 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0006	THP-1	Cancer cell line	Male
CVCL_0R21	THP-1/DC-SIGN	Cancer cell line	Male
CVCL_0R25	THP-1(NCI)	Cancer cell line	Male
CVCL_0R26	THP-1(NCI)/DC-SIGN	Cancer cell line	Male
CVCL_3426	THP-1h	Cancer cell line	Male
CVCL_3427	THP-1l	Cancer cell line	Male
CVCL_4V22	THP-1/ara-C	Cancer cell line	Male
CVCL_5115	A-THP-1	Cancer cell line	Male
CVCL_5I76	THP1-defCASP1	Cancer cell line	Male
CVCL_5I77	THP1-NLRC4	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice